“Johnson & Johnson beats on earnings, hikes full-year guidance as medtech sales surge”
July 20, 2023
“Johnson & Johnson on Thursday reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations, and lifted its full-year guidance as sales from the company’s medtech business jumped…
That increased demand has been observed by health insurers like UnitedHealth Group and Elevance Health. Here’s how J&J results compared with Wall Street expectations, based on a survey of analysts by Refinitiv:
- Earnings per share: $2.80 adjusted, vs. $2.62 expected
- Revenue: $25.53 billion, vs. $24.62 billion expected
Shares of J&J rose about 2% in premarket trading Thursday. J&J’s stock has dropped more than 10% for the year, putting the company’s market value at roughly $412 billion…”
https://www.cnbc.com/2023/07/20/johnson-johnson-jnj-q2-earnings-report-2023.html